Systemic Therapy in Head and Neck Cancer: Changing Paradigm

Indian Journal of Surgical Oncology

Volumn 4, Issue 1, 2013, Pages 19-26

  Purohit, Samit ^a,b   Bhise, Rohan ^a   Lokanatha, D ^a   Govindbabu, K ^a  

^a KMIO   (India)

^b KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Chemoevolution in head and neck cancer; Chemtherapy in head and neck cancer; HPV; MACH NC; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PEMETREXED; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK CANCER; HUMAN; INDUCTION CHEMOTHERAPY; LARYNGECTOMY; LARYNX CANCER; MULTIPLE CYCLE TREATMENT; NUTRITIONAL SUPPORT; ORGAN PRESERVATION; OROPHARYNX CANCER; OVERALL SURVIVAL; PRESERVATION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84874378060     PISSN: 09757651     EISSN: 09766952     Source Type: Journal    
DOI: 10.1007/s13193-012-0197-4     Document Type: Review

References (44)

1. Posner MR (2010) Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice. ASCO. 205-209.
2. Dayyani F, Etzel CJ, Liu M, Ho C-H, Lippman SM, Tsao AS (2010) Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2: 15.
3. Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22: 1071-1077.
4. Cambell JB, Dorman EB, McCormick M et al (1987) A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-flurouracil in end stage head and neck cancer. Acta Otolaryngol 103: 519-528.
5. Morton RP, Rugman F, Dorman EB et al (1992) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 15: 283-289.
6. Eisenberger M, Hornedo J, Silva H et al (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous cell carcinoma of head and neck. J Clin Oncol 4: 1506-1509.
7. Eisenberger M, Krasnow S, Ellenberg S et al (1989) A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 7: 1341-1345.
8. Schornagel JH, Verweij J, de Mulder PH et al (1995) Randomised phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of head and neck: a European Organisation for research and treatment of cancer head and neck cancer cooperative group study. J Clin Oncol 13: 1649-1655.
9. Tapazoglou E, Kish J, Ensley J et al (1986) The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57: 1105-1109.
10. Buesa JM, Fernandez R, Esteban E et al (1991) Phase II trial of ifosfamide in recurrent and metastatic head and cancer. Ann Oncol 2: 151-152.
11. Cervellino JC, Araujo CE, Pirisi C et al (1991) Ifosfamide and mesna in treatment of advanced squamous cell carcinoma of head and neck. Oncology 48: 89-92.
12. Couteau C, Chouaki N, Leyvraz S et al (1999) A phase II study of docetaxel in metastatic squamous cell carcinoma of head and neck. Br J Cancer 81: 457-462.
13. Dreyfuss AI, Clark JR, Norris CM et al (1996) Docetaxel: an active drug for squamous cell carcinoma of head and neck. J Clin Oncol 14: 1672-1678.
14. Gebbia V, Testa A, Cannata G et al (1996) Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 32A: 901-902.
15. Smith RE, Thornton DE, Allen J (1995) A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22: 41-46.
16. Jacob's C, Meyers F, Hendrickson C et al (1983) A randomized phase III study of cisplatin with or without methotrexate for recurrent and squamous cell carcinoma of head and neck: a North California Oncology group study. Cancer 52: 1563-1569.
17. Drelichman A, Cummings G, AL-Sarraf M et al (1983) A randomized trial of the combination of cisplatin, oncovin and bleomycin (COB) versus methotreaxte in patients with advanced squamous cell carcinoma of the head and neck. Cancer 52: 399-403.
18. Williams S, Velex-Garcia E, Essessee I et al (1986) Chemotherapy for head and neck cancer: comparison of cisplatin, vinblastin, bleomycin versus methotrexate. Cancer 57: 18-23.
19. Jacobs C, Lyman G, Velez-garcia E et al (1992) A phase III randomized study comparing cisplatin and flurouracil as single agents and in combination for advanced squamous cell carcinoma of head and neck. J Clin Oncol 10: 257-263.
20. Forastiere A, Metch B, Schuller D et al (1992) Randomised comparison of cisplatin plus 5 flurouracil and carboplatin plus flurouracil versus methotrexate in advanced squamous-cell carcinoma of head and neck: a south west oncology group study. J Clin Oncol 10: 1245-1251.
21. Clavel M, Vermoken JB, Cognetti F et al (1994) Randomised comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5 Fu (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5: 521-526.
22. Browman GP, Cronin L (1994) Standard chemotherapy in squamous cell head and neck cancer: what have we learned from randomized trials. Semin Oncol 21: 311-319.
23. Murphy B, Li Y, Cella D et al (2001) Phase III study comparing cisplatin (C) & 5 flurouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head and neck cancer. Proc Annu Meet Am Soc Clin Oncol 20: A894.
24. Schoffski P, Catimel G, Planting AST et al (1999) Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10: 119-122.
25. Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111.
26. Randolf VL, Vellejo A, Spiro RH et al (1978) Combination therapy for advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 41: 460-467.
27. Hong WK, Shapshay SM, Bhutani R et al (1979) Induction chemotherapy in advanced squamous head and neck cancer with high dose cisplatinum and bleomycin infusion. Cancer 44: 19-25.
28. De Andres L, Brunet J, Lopez-Pousa A et al (1995) Randomised trial of neoadjuvant cisplatin and flurouracil versus carboplatin and flurouracil in patients with stage IV-Mo head and neck cancer. J Clin Oncol 13: 1493-1500.
29. Domenge C, Hill C, Lefebvre JL et al (2000) Randomised trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Grouoe d'Etude des Tumeurs de la tete et du Cou (GETTEC). Br J Cancer 83: 1594-1598.
30. (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The department of veterans affairs laryngeal cancer study group. N Engl J Med 324: 1685-1690.
31. Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of European Organisation for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88: 890-899.
32. Forastiere AA, Goepfert H et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098.
33. Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12: 153-159.
34. Blanchard P, Baujat B, Holostenco V et al (2011) Meta-analysis of Chemotherapy in Head and Neck cancer (MACH-NC). A comprehensive analysis by tumour site. Radiother Oncol 100: 33-40.
35. Cooper JS, Pajak TF, Forastiere AA et al (2004) Post operative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of head and neck. N Engl J Med 350: 1937-1944.
36. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952.
37. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N Engl J Med 354: 567-578.
38. Herbst RS, Arquette M, Shin DM et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck cancer. J Clin Oncol 23: 5578-5587.
39. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646.
40. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
41. Babu KG, Viswanath L, Reddy BK et al (2010) An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J Clin Oncol 28: 15s, suppl; abstr 5530.
42. Hong WK, Lippman SM, Itri LM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of head and neck. N Engl J Med 323: 795-801.
43. Argiris A, Karamouzis MV, Gooding WE et al (2010) Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer: Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8.
44. Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A et al (2007) Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 117: 1173-1179.